{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:37:20Z","timestamp":1788262640851,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["worldallergyorganizationjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Allergy Organization Journal"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.waojou.2022.100676","type":"journal-article","created":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T17:53:04Z","timestamp":1659289984000},"page":"100676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Current and emerging biologic therapies targeting eosinophilic disorders"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5341-4552","authenticated-orcid":false,"given":"Mitchell M.","family":"Pitlick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanai","family":"Pongdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.waojou.2022.100676_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The eosinophil","volume":"24","author":"Rothenberg","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.waojou.2022.100676_bib2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jaci.2012.07.024","article-title":"Workshop report from the national institutes of health taskforce on the research needs of eosinophil-associated diseases (TREAD)","volume":"130","author":"Bochner","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100676_bib3","first-page":"577","article-title":"Novel therapies for eosinophilic disorders","volume":"35","author":"Bochner","year":"2015","journal-title":"Immunol Allergy Clin"},{"key":"10.1016\/j.waojou.2022.100676_bib4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fmed.2018.00049","article-title":"Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma","volume":"5","author":"Roufosse","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.waojou.2022.100676_bib5","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/0008-8749(91)90120-Z","article-title":"Characterization of the human IL-5 receptors on eosinophils","volume":"133","author":"Migita","year":"1991","journal-title":"Cell Immunol"},{"key":"10.1016\/j.waojou.2022.100676_bib6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2222.2008.03173.x","article-title":"Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors","volume":"39","author":"Bochner","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.waojou.2022.100676_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.pharmthera.2012.06.005","article-title":"Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions","volume":"135","author":"Kiwamoto","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.waojou.2022.100676_bib8","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.jaci.2018.10.066","article-title":"Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: receptor expression and targeting using chimeric antibodies","volume":"143","author":"Legrand","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100676_bib9","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s40265-015-0513-8","article-title":"Mepolizumab: first global approval","volume":"75","author":"Keating","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.waojou.2022.100676_bib10","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40265-016-0583-2","article-title":"Reslizumab: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.waojou.2022.100676_bib11","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/17425255.2017.1359253","article-title":"Pharmacokinetic\/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma","volume":"13","author":"Matera","year":"2017","journal-title":"Expet Opin Drug Metabol Toxicol"},{"key":"10.1016\/j.waojou.2022.100676_bib12","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100676_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126219","article-title":"Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis","volume":"4","author":"Youngblood","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.waojou.2022.100676_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000501637","article-title":"AK002, a humanized sialic acid-binding immunoglobulin-like lectin-8 antibody that induces antibody-dependent cell-mediated cytotoxicity against human eosinophils and inhibits mast cell-mediated anaphylaxis in mice","volume":"180","author":"Youngblood","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.waojou.2022.100676_bib15","first-page":"144","article-title":"Heterogeneity of bronchitis in airway diseases in tertiary care clinical practice","volume":"18","author":"D'Silva","year":"2011","journal-title":"Can Respir J"},{"key":"10.1016\/j.waojou.2022.100676_bib16","first-page":"559","article-title":"Eosinophilic endotype of asthma","volume":"36","author":"Aleman","year":"2016","journal-title":"Immunol Allergy Clin"},{"key":"10.1016\/j.waojou.2022.100676_bib17","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.waojou.2022.100676_bib18","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.waojou.2022.100676_bib19","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.waojou.2022.100676_bib20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.waojou.2022.100676_bib21","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.waojou.2022.100676_bib22","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.clinthera.2019.07.007","article-title":"Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study","volume":"41","author":"Khurana","year":"2019","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.waojou.2022.100676_bib23","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/ppul.24508","article-title":"Subcutaneous\u00a0mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma","volume":"54","author":"Gupta","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.waojou.2022.100676_bib24","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2019.08.005","article-title":"Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype","volume":"144","author":"Gupta","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100676_bib25","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.waojou.2022.100676_bib26","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.waojou.2022.100676_bib27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.waojou.2022.100676_bib28","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety\u00a0of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.waojou.2022.100676_bib29","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.waojou.2022.100676_bib30","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.waojou.2022.100676_bib31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.waojou.2022.100676_bib32","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/JAA.S227170","article-title":"Two-year integrated efficacy and safety analysis of benralizumab in severe asthma","volume":"12","author":"FitzGerald","year":"2019","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.waojou.2022.100676_bib33","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","article-title":"Integrated safety and efficacy among patients receiving benralizumab for up to 5 years","volume":"9","author":"Korn","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2022.100676_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study","volume":"10","author":"Menzies-Gow","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.waojou.2022.100676_bib35","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaci.2018.08.031","article-title":"Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison","volume":"143","author":"Busse","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100676_bib36","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-015-8506-7","article-title":"Hypereosinophilic syndrome","volume":"50","author":"Curtis","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.waojou.2022.100676_bib37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11899-018-0448-8","article-title":"Diagnosis and novel approaches to the treatment of hypereosinophilic syndromes","volume":"13","author":"Dispenza","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.waojou.2022.100676_bib38","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/asheducation-2018.1.326","article-title":"Hypereosinophilic syndrome: approach to treatment in the era of precision medicine","volume":"2018","author":"Klion","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.waojou.2022.100676_bib39","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/ajh.25617","article-title":"World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management","volume":"94","author":"Shomali","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.waojou.2022.100676_bib40","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.waojou.2022.100676_bib41","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100676_bib42","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100676_bib43","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.waojou.2022.100676_bib44","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/rheumatology\/kes171","article-title":"Increased production of IL-5 and dominant Th2-type response in airways of Churg-Strauss syndrome patients","volume":"51","author":"Jakiela","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.waojou.2022.100676_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised international chapel hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.waojou.2022.100676_bib46","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.waojou.2022.100676_bib47","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0091-6749(97)80019-X","article-title":"IL-5 synthesis is upregulated in human nasal polyp tissue","volume":"99","author":"Bachert","year":"1997","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100676_bib48","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100676_bib49","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2500\/ajra.2014.28.4033","article-title":"Differences in initial immunoprofiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps","volume":"28","author":"Van Zele","year":"2014","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.waojou.2022.100676_bib50","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.waojou.2022.100676_bib51","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100676_bib52","first-page":"683","article-title":"Management of eosinophilic esophagitis from childhood to adulthood","volume":"8","author":"Furuta","year":"2012","journal-title":"Gastroenterol Hepatol (NY)"},{"key":"10.1016\/j.waojou.2022.100676_bib53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2011.02.040","article-title":"Eosinophilic esophagitis: updated consensus recommendations for children and adults","volume":"128","author":"Liacouras","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100676_bib54","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2011.07.044","article-title":"An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis","volume":"141","author":"Assa'ad","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.waojou.2022.100676_bib55","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaci.2011.11.044","article-title":"Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial","volume":"129","author":"Spergel","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100676_bib56","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/MPG.0000000000001840","article-title":"Safety and efficacy of reslizumab for children and adolescents with eosinophilic esophagitis treated for 9 years","volume":"66","author":"Markowitz","year":"2018","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.waojou.2022.100676_bib57","series-title":"Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2\/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases","year":"2021"},{"key":"10.1016\/j.waojou.2022.100676_bib58","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.anai.2018.06.013","article-title":"Eosinophilic gastrointestinal diseases beyond eosinophilic esophagitis","volume":"121","author":"Egan","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.waojou.2022.100676_bib59","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s12016-019-08732-1","article-title":"Eosinophilic gastrointestinal disorders","volume":"57","author":"Gonsalves","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.waojou.2022.100676_bib60","doi-asserted-by":"crossref","first-page":"984","DOI":"10.14309\/ajg.0000000000000228","article-title":"Increasing rates of diagnosis, substantial Co-occurrence, and variable treatment patterns of eosinophilic gastritis, gastroenteritis, and colitis based on 10-year data across a multicenter consortium","volume":"114","author":"Pesek","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.waojou.2022.100676_bib61","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti-siglec-8 antibody for eosinophilic gastritis and duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.waojou.2022.100676_bib62","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1111\/jdv.15720","article-title":"Benefit of benralizumab treatment in a patient with chronic symptomatic dermographism","volume":"33","author":"Bergmann","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.waojou.2022.100676_bib63","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/ddg.13481","article-title":"Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria","volume":"16","author":"Magerl","year":"2018","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.waojou.2022.100676_bib64","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1111\/jdv.14594","article-title":"Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria","volume":"32","author":"Maurer","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.waojou.2022.100676_bib65","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaip.2017.10.020","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome successfully treated with mepolizumab","volume":"6","author":"Ange","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2022.100676_bib66","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jaip.2020.09.039","article-title":"Benralizumab for severe DRESS in two COVID-19 patients","volume":"9","author":"Schmid-Grendelmeier","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2022.100676_bib67","first-page":"e9684","article-title":"Mepolizumab\u00a0as possible treatment for allergic bronchopulmonary aspergillosis: a review of eight cases","volume":"12","author":"Tolebeyan","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.waojou.2022.100676_bib68","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00408-020-00336-3","article-title":"Real-life study of mepolizumab in idiopathic chronic eosinophilic pneumonia","volume":"198","author":"Brenard","year":"2020","journal-title":"Lung"},{"key":"10.1016\/j.waojou.2022.100676_bib69","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.jaip.2019.10.013","article-title":"Eosinophilic bronchiolitis successfully treated with mepolizumab","volume":"8","author":"Takeshita","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2022.100676_bib70","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13223-020-00423-3","article-title":"Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report","volume":"16","author":"Caruso","year":"2020","journal-title":"Allergy Asthma Clin Immunol"}],"container-title":["World Allergy Organization Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455122000527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455122000527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:44:56Z","timestamp":1761849896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1939455122000527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":70,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1939455122000527"],"URL":"https:\/\/doi.org\/10.1016\/j.waojou.2022.100676","relation":{},"ISSN":["1939-4551"],"issn-type":[{"value":"1939-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and emerging biologic therapies targeting eosinophilic disorders","name":"articletitle","label":"Article Title"},{"value":"World Allergy Organization Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.waojou.2022.100676","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc. on behalf of World Allergy Organization.","name":"copyright","label":"Copyright"}],"article-number":"100676"}}